Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net Revenue $ 2,406,391 $ 921
Operating expenses:    
Direct costs and expenses 1,573,441 87
Research and development 393,639 369,617
Clinical development 48,960 19,628
Selling, general and administrative 2,185,944 1,147,875
Depreciation and amortization 149,637 21,684
Total operating expenses 4,351,621 1,558,891
Loss from operations (1,945,230) (1,557,970)
Other income (expense):    
Interest income 6,127 38,654
Interest expense (23,550) (1,655)
Other expense 4,510
Total other expense (12,913) 36,999
Net loss before provision for income taxes (1,958,143) (1,520,971)
Income tax expense (3,672) (11,819)
Net loss $ (1,961,815) $ (1,532,790)
Net loss per common share, basic $ (0.20) $ (0.18)
Net loss per common share, diluted $ (0.20) $ (0.18)
Weighted average common shares outstanding, basic 9,915,426 8,433,689
Weighted average common shares outstanding, diluted 9,915,426 8,433,689